WHO highlights expanded TB drug resistance catalogue based on 71,784 isolates
The technical document separates testing and isolate counts by data stage. WHO’s announcement and catalogue page display different dates.
Event / data period:
Published: · Updated:

The World Health Organization on 10 November 2026 highlighted an expanded catalogue for interpreting genetic mutations associated with resistance to tuberculosis medicines. The reference combines evidence from more than 71,000 clinical isolates from over 75 countries, according to WHO. Its authors stress that the catalogue supports laboratory interpretation and is not a standalone tool for making treatment decisions.
The third edition brings together whole genome sequencing and laboratory drug susceptibility results for isolates of the Mycobacterium tuberculosis complex. Researchers compare genetic changes with whether a bacterial sample showed resistance in phenotypic testing. The resulting classifications help laboratories and researchers interpret sequencing results, but an association in a reference list is not the same as a complete assessment of an individual patient.
WHO's 10 November departmental update says the third edition was published that day. Its separate publication page for the same document displays 30 October 2026. The organization does not explain the difference on those pages. This report dates the announcement to 10 November and identifies the catalogue page's earlier date separately, rather than treating the two dates as interchangeable.
The technical document gives more precise figures for the stages of its dataset: 715,707 phenotypic test results were collected for 85,794 isolates, whole genome data were available for 81,335 isolates and 71,784 remained in the final analysis after curation and quality control. It says 75 countries contributed at least five isolates and three countries contributed at least 5,000 each. Those country groups overlap and should not be added together.
The 71,000 figure counts clinical isolates in the reference dataset, not necessarily 71,000 different patients or new infections. WHO says the dataset is 37% larger by volume and covers 12% more countries than the second edition, published in 2023. The percentages describe the change in the catalogue's evidence base, not a rise in tuberculosis cases or drug resistance. The first edition appeared in 2021.
The new edition expands evidence for medicines including pretomanid and cycloserine and updates the statistical and bioinformatic methods used to classify mutations. Its intended uses include developing and evaluating molecular tests, supporting reference laboratories, surveillance and research. WHO also adds practical explanations and frequently asked questions to help users apply the material.
The catalogue's mutation list has five confidence groups, ranging from association with resistance to no association, with a separate group for uncertain significance. But WHO warns against relying on that list in isolation. The genetic context of a sample can change how a mutation is interpreted, and additional rules address factors such as interactions between variants and resistance levels. Mutations absent from the graded list require the accompanying framework as well.
The distinction matters because sequencing detects genetic variation, whereas phenotypic testing observes how the bacterial sample responds to a medicine under laboratory conditions. The catalogue says sequencing approaches do not capture every resistance mechanism and that continued access to high quality phenotypic testing is essential. It also notes limitations and variability in the testing methods used to establish those associations.
More isolates and countries can strengthen the evidence available for classification, but they do not prove equal representation of every setting or guarantee that every mutation has a clear interpretation. An uncertain classification means the available evidence does not support a definitive association under the catalogue's criteria. It should not automatically be described either as confirmed resistance or as proof of susceptibility.
WHO states that patient level interpretation must combine catalogue classifications with laboratory quality assurance, clinical assessment and national treatment guidelines. This is particularly important when interpreting results for newer or repurposed medicines whose resistance mechanisms are less completely understood. The publication does not claim that the catalogue replaces a clinician, diagnoses a patient by itself or makes every test result conclusive.
The November update therefore marks a change in the information available to professionals, not evidence that a new treatment has been approved or that access to testing has improved everywhere. The expanded dataset, its rules and its limits should be read together when assessing what the catalogue can contribute to tuberculosis care and surveillance.
Data
WHO issues update on resistance mutation catalogue
WHO described the scope and use of the third edition; the catalogue page displays a different date.
- · Occurred
WHO issues update on resistance mutation catalogue
WHO described the scope and use of the third edition; the catalogue page displays a different date.
Methodology
10 November is the announcement date; the publication page of the same document displays 30 October 2026.
Updated:
Stages of the catalogue dataset
Technical document section 3.3; test results and isolates are different units. The date is the publication page date, not the sampling period.
- Phenotypic test results collected
- 715,707 count
- 2026-10-30 · Observed
- Isolates associated with collected results
- 85,794 count
- 2026-10-30 · Observed
- Isolates with matching whole genome data
- 81,335 count
- 2026-10-30 · Observed
- Isolates in final analysis after curation and quality control
- 71,784 count
- 2026-10-30 · Observed
Methodology
Technical document section 3.3; test results and isolates are different units. The date is the publication page date, not the sampling period.
Updated:
Overlapping thresholds of country contributions
Technical document section 3.3: thresholds are per country and groups overlap, so the counts are not additive.
- Countries contributing at least five isolates each
- 75 count
- 2026-10-30 · Observed
- Countries contributing at least 5,000 isolates each
- 3 count
- 2026-10-30 · Observed
Methodology
Technical document section 3.3: thresholds are per country and groups overlap, so the counts are not additive.
Updated:
Subjects and places
Subject proposals
- Communicable diseaseSuggested
- Subject suggested from the title or summary: TBwww.who.int ↗www.who.int ↗iris.who.int ↗